US2008206867A1PendingUtilityA1
Fc variants with optimized Fc receptor binding properties
Est. expiryOct 3, 2025(expired)· nominal 20-yr term from priority
Inventors:John DesjarlaisSher Bahadur KarkiGregory Alan LazarJohn O. RichardsGregory MooreDavid F. Carmichael
C07K 2317/41C07K 2317/77C07K 16/2887C07K 16/2863C07K 2317/52C07K 2317/72C07K 16/00C07K 16/30C07K 2317/732
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
Claims
exact text as granted — not AI-modified1 . An Fc variant of a parent Fc polypeptide comprising at least a first and a second substitution, said first and second substitutions each at a position selected from group consisting of 234, 235, 236, 239, 267, 268, 293, 295, 324, 327, 328, 330, and 332, wherein said Fc variant exhibits an increase in affinity for one or more receptors selected from the group consisting of FcγRI, FcγRIIa, and FcγRIIIa as compared to the increase in a affinity of said Fc variant for the FcγRIIb receptor, wherein the numbering is according to the EU index and wherein said increases in affinities are relative to said parent polypeptide.
2 . An Fc variant according to claim 1 , wherein at least one of said substitutions is selected from the group consisting of 234G, 234I, 235D, 235E, 235I, 235Y, 236A, 236S, 239D, 267D, 267E, 267Q, 268D, 268E, 293R, 295E, 324G, 324I, 327H, 328A, 328F, 328I, 330I, 330L, 330Y, 332D, and 332E.
3 . An Fc variant according to claim 2 , wherein said first and second substitutions are each selected from the group consisting of 234G, 234I, 235D, 235E, 235I, 235Y, 236A, 236S, 239D, 267D, 267E, 267Q, 268D, 268E, 293R, 295E, 324G, 324I, 327H, 328A, 328F, 328I, 330I, 330L, 330Y, 332D, and 332E.
4 . An Fc variant according to claim 1 , wherein said Fc polypeptide further has increased affinity for FcγRI relative to the parent Fc polypeptide.
5 . An antibody or Fc fusion comprising an Fc variant according to claim 1 .
6 . An Fc variant according to claim 1 , wherein said modification is a reduced level of fucosylation relative to said parent Fc variant.
7 . An Fc variant according to claim 1 , wherein said Fc variant mediates improved phagocytosis by FcγRIIa expressing cells relative to said parent Fc polypeptide.
8 . A composition comprising the Fc variant of claim 1 , wherein said Fc variant comprises a glycosylated Fc region, wherein about 80-100% of the glycosylated Fc polypeptide in the composition comprises a mature core carbohydrate structure with no fucose.
9 . An Fc variant of a parent Fc polypeptide comprising at least a first and a second substitution, said first and second substitutions each at a position selected from group consisting of 234, 235, 236, 239, 267, 268, 293, 295, 324, 327, 328, 330, and 332, wherein said Fc variant exhibits an increase in a affinity of said Fc variant for the FcγRIIb receptor as compared to the increase in affinity for one or more receptors selected from the group consisting of FcγRI, FcγRIIa, and FcγRIIIa, wherein the numbering is according to the EU index and wherein said increases in affinities are relative to said parent polypeptide.
10 . An Fc variant according to claim 9 , wherein at least one of said first and second substitutions is selected from the group consisting of 236A, 236S, 239D, 267D, 267E, 267Q, 268D, 268E, 293R, 295E, 324G, 324I, 327H, 328A, 328F, 330I, 330L, 330Y, 332D, and 332E.
11 . An Fc variant according to claim 10 , wherein each of said first and second substitutions is selected from the group consisting of 236A, 236S, 239D, 267D, 267E, 267Q, 268D, 268E, 293R, 295E, 324G, 324I, 327H, 328A, 328F, 330I, 330L, 330Y, 332D, and 332E.
12 . An Fc variant comprising a first substitution at a position selected from the group consisting of 234, 235, 236, 239, 267, 268, 293, 295, 324, 327, 328, 330, and 332, and a second substitution selected from the group consisting of 247L, 255L, 270E, 280H, 280Q, 280Y, 298A, 298T, 392T, 396L, 326A, 326D, 326E, 326W, 333A, 334A, 334L, and 421K.
13 . The Fc variant according to claim 12 , said substitution comprising at least two amino acids positions selected from the group consisting of 235, 236, 237, 238, 239, 265, 266, 267, 269, 270, 295, 296, 298, 299, 325, 326, 327, 328, 329, 330, and 332.
14 . An Fc variant comprising a first substitution at a position selected from the group consisting of 239 and 332, and a second substitution at a position selected from the group consisting of 233, 234, 241, 264, 265, 268, 328, 333 and 334.
15 . An Fc variant according to claim 14 further comprising a substitution at position 239 and position 332.
16 . An Fc variant according to claim 14 , wherein said first substitution is selected from the group consisting of 239D and 332E.
17 . An Fc variant according to claim 14 , wherein said second substitution is selected from the group consisting of 233H, 234K, 241H, 241Q, 241R, 264T, 265N, 265K, 265H, 265Q, 265G, 265S, 265L, 268E, 328K, 333T, 333H, and 334R.
18 . A method of activating an receptor selected from the group consisting of FcγRI, FcγRIIa, and FcγRIIIa relative to FcγRIIb receptor, said method comprising contacting a cell comprising a receptor selected from the group consisting of FcγRI, FcγRIIa, and FcγRIIIa with an Fc variant according to claim 1 .
19 . A method of activating an FcγRIIb receptor relative to a receptor selected from the group consisting of FcγRI, FcγRIIa, and FcγRIIIa, said method comprising contacting a cell comprising a receptor selected from the group consisting of FcγRI, FcγRIIa, and FcγRIIIa with an Fc variant according to claim 9 .
20 . An Fc variant of a parent mouse Fc polypeptide, said Fc variant comprising a substitution at a position selected from the group consisting of 236, 239, 268, 330, and 332.
21 . An Fc variant according to claim 19 , wherein said substitution is selected from the group consisting of 236A, 239D, 268E, 330Y, and 332E.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.